Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system

BACKGROUND: Oral factor Xa inhibitors (FXaI) can be administered in fixed doses without the need for routine laboratory monitoring. Anti-Xa assays can estimate anticoagulant effect for specific FXaI's. The aim of this study was to characterize anti-Xa levels in patients taking apixaban or rivar...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakowenko, Nicholas, Nguyen, Steffany, Ruegger, Melanie, Dinh, Ashley, Salazar, Eric, Donahue, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474843/
https://www.ncbi.nlm.nih.gov/pubmed/32947066
http://dx.doi.org/10.1016/j.thromres.2020.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474843/
https://www.ncbi.nlm.nih.gov/pubmed/32947066
http://dx.doi.org/10.1016/j.thromres.2020.09.002

Ejemplares similares